Literature DB >> 16249475

The impact of age-related macular degeneration on health status utility values.

Mireia Espallargues1, Carolyn J Czoski-Murray, Nicholas J Bansback, Jill Carlton, Grace M Lewis, Lindsey A Hughes, Christopher S Brand, John E Brazier.   

Abstract

PURPOSE: To estimate health status utility values in patients with age-related macular degeneration (ARMD) associated with visual impairments, by using preference-based measures of health.
METHOD: This was a cross-sectional study involving patients with unilateral or bilateral ARMD who attended a large teaching hospital. Patients underwent visual tests (near and distant visual acuity [VA] and contrast sensitivity [CS]) and completed health status questionnaires including the Index of Visual Function (VF)-14 and three preference-based measures (the Health Utilities Index Mark III [HUI-3], the EuroQoL Health Questionnaire [EQ-5D], and the Short Form 6D Health Status Questionnaire [SF-6D]) and the time tradeoff (TTO). The mean health status is presented for five groups, defined according to the VA in the better-seeing eye and for four CS groups.
RESULTS: Two hundred nine patients were recruited with substantial loss of visual function as obtained by visual tests (mean decimal VA in the better-seeing eye: 0.2) and self-report (mean VF-14 score: 41.5). The mean (+/-SD) utilities were 0.34 +/- 0.28 for HUI-3, 0.66 +/- 0.14 for SF-6D, 0.72 +/- 0.22 for EQ-5D, and 0.64 +/- 0.31 for TTO. The HUI-3 had the highest correlation with VA and CS (0.40 and -0.34), followed by TTO (0.25 and -0.21). Across the VA and CS groups, only HUI3 and TTO had a significant linear trend (P < 0.05). In a regression model with CS and VA as explanatory variables, only the coefficient on CS was statistically significant.
CONCLUSIONS: ARMD is associated with a substantial impact on patients' health status, but this was not reflected in two of the generic preference-based measures used. The HUI-3 seems to be the instrument of choice for use in economic evaluations in which community data are needed. It may be more appropriate to base economic models on CS or some combination of CS and VA rather than on VA alone.

Entities:  

Mesh:

Year:  2005        PMID: 16249475     DOI: 10.1167/iovs.05-0072

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  48 in total

1.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

Review 2.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

3.  Estimating informal care inputs associated with EQ-5D for use in economic evaluation.

Authors:  Donna Rowen; Simon Dixon; Mónica Hernández-Alava; Clara Mukuria
Journal:  Eur J Health Econ       Date:  2015-08-15

4.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation.

Authors:  Christine M McDonough; Tor D Tosteson; Anna N A Tosteson; Alan M Jette; Margaret R Grove; James N Weinstein
Journal:  Med Decis Making       Date:  2010-11-22       Impact factor: 2.583

6.  Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.

Authors:  Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki
Journal:  Qual Life Res       Date:  2011-08-04       Impact factor: 4.147

Review 7.  Valuing health States for use in cost-effectiveness analysis.

Authors:  John Brazier
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  The classification systems of the EQ-5D, the HUI II and the SF-6D: what do they have in common?

Authors:  Uwe Konerding; Jörn Moock; Thomas Kohlmann
Journal:  Qual Life Res       Date:  2009-09-01       Impact factor: 4.147

9.  Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?

Authors:  Michela Tinelli; Mandy Ryan; Christine Bond; Anthony Scott
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

10.  Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.

Authors:  Anne M Rentz; Jonathan W Kowalski; John G Walt; Ron D Hays; John E Brazier; Ren Yu; Paul Lee; Neil Bressler; Dennis A Revicki
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.